These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 28648526)
1. Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs. Congreve M; Oswald C; Marshall FH Trends Pharmacol Sci; 2017 Sep; 38(9):837-847. PubMed ID: 28648526 [TBL] [Abstract][Full Text] [Related]
2. Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions. Lu S; Zhang J J Med Chem; 2019 Jan; 62(1):24-45. PubMed ID: 29457894 [TBL] [Abstract][Full Text] [Related]
3. Novel Allosteric Modulators of G Protein-coupled Receptors. Gentry PR; Sexton PM; Christopoulos A J Biol Chem; 2015 Aug; 290(32):19478-88. PubMed ID: 26100627 [TBL] [Abstract][Full Text] [Related]
4. Allosteric Modulators of the Class A G Protein Coupled Receptors. Tschammer N Adv Exp Med Biol; 2016; 917():185-207. PubMed ID: 27236557 [TBL] [Abstract][Full Text] [Related]
5. Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives. Urwyler S Pharmacol Rev; 2011 Mar; 63(1):59-126. PubMed ID: 21228259 [TBL] [Abstract][Full Text] [Related]
6. Structural Basis for Allosteric Modulation of Class B G Protein-Coupled Receptors. Wootten D; Miller LJ Annu Rev Pharmacol Toxicol; 2020 Jan; 60():89-107. PubMed ID: 31454292 [TBL] [Abstract][Full Text] [Related]
7. Allosteric modulation of GPCRs: From structural insights to in silico drug discovery. Persechino M; Hedderich JB; Kolb P; Hilger D Pharmacol Ther; 2022 Sep; 237():108242. PubMed ID: 35863587 [TBL] [Abstract][Full Text] [Related]
8. GPCR structures in drug design, emerging opportunities with new structures. Tautermann CS Bioorg Med Chem Lett; 2014 Sep; 24(17):4073-9. PubMed ID: 25086683 [TBL] [Abstract][Full Text] [Related]
9. Emerging opportunities for allosteric modulation of G-protein coupled receptors. Wang CI; Lewis RJ Biochem Pharmacol; 2013 Jan; 85(2):153-62. PubMed ID: 22975406 [TBL] [Abstract][Full Text] [Related]
10. Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target. Janero DR; Thakur GA Expert Opin Drug Discov; 2016 Dec; 11(12):1223-1237. PubMed ID: 27712124 [TBL] [Abstract][Full Text] [Related]
11. Potential for the Rational Design of Allosteric Modulators of Class C GPCRs. Christopher JA; Doré AS; Tehan BG Curr Top Med Chem; 2017; 17(1):71-78. PubMed ID: 27448651 [TBL] [Abstract][Full Text] [Related]
12. Class A GPCRs: Structure, Function, Modeling and Structure-based Ligand Design. Cong X; Topin J; Golebiowski J Curr Pharm Des; 2017 Nov; 23(29):4390-4409. PubMed ID: 28699533 [TBL] [Abstract][Full Text] [Related]
13. Allosteric modulation of kinases and GPCRs: design principles and structural diversity. Lewis JA; Lebois EP; Lindsley CW Curr Opin Chem Biol; 2008 Jun; 12(3):269-80. PubMed ID: 18342020 [TBL] [Abstract][Full Text] [Related]
14. Functional and structural perspectives on allosteric modulation of GPCRs. Langmead CJ; Christopoulos A Curr Opin Cell Biol; 2014 Apr; 27():94-101. PubMed ID: 24680434 [TBL] [Abstract][Full Text] [Related]
15. Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5. Bian Y; Feng Z; Yang P; Xie XQ AAPS J; 2017 Jul; 19(4):1235-1248. PubMed ID: 28560482 [TBL] [Abstract][Full Text] [Related]
16. Current and Future Challenges in GPCR Drug Discovery. Topiol S Methods Mol Biol; 2018; 1705():1-21. PubMed ID: 29188556 [TBL] [Abstract][Full Text] [Related]